The clinical and preclinical results are consistent with other studies of CRC tumour samples from patients that were never exposed to anti-EGFR antibodies as it has been demonstrated that they may carry subclonal RAS mutations but not pre-existing EGFR ECD mutations10, 12, 21. The gene discussed is EGFR; the disease is colorectal carcinoma.